Nosocomial meningitis caused by ESBL- and OXA-48-producing Klebsiella pneumoniae and treated with ceftazidime-avibactam. Report of one case and review of the literature

Rev Esp Quimioter 2022;35(6): 572-576 572 During his stay in the ICU, he underwent a rectal culture that resulted positive for ESBLand OXA-48-producing K. pneumoniae, which was isolated in selective chromogenic media (CHROMID ESBL and CHROMID CARBA SMART (bioMérieux)). Consequently, the appropriate isolation measures were implemented. Afterwards, the patient developed a mechanical ventilation-associated pneumonia due to such pathogen and, therefore, treatment with CAZ-AVI was decided.

[1]  A. Inkaya,et al.  Carbapenem-resistant Klebsiella pneumoniae meningitis and abscess treated with ceftazidime-avibactam. , 2022, Enfermedades infecciosas y microbiologia clinica.

[2]  A. Inkaya,et al.  Carbapenem-resistant Klebsiella pneumoniae meningitis and abscess treated with ceftazidime-avibactam. , 2021, Enfermedades infecciosas y microbiologia clinica.

[3]  P. Tamma,et al.  Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  M. Bassetti,et al.  Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance , 2020, Antibiotics.

[5]  R. Bonomo,et al.  Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam , 2020, Open forum infectious diseases.

[6]  R. Nau,et al.  Intrathecal Antibacterial and Antifungal Therapies , 2020, Clinical Microbiology Reviews.

[7]  M. Meschiari,et al.  Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales , 2020, Antibiotics.

[8]  M. Chang,et al.  Post-neurosurgical meningitis caused by KPC-producing Klebsiella pneumoniae: report of two cases , 2019, Revista do Instituto de Medicina Tropical de Sao Paulo.

[9]  Lei Liu,et al.  The treatment of nosocomial meningitis and brain abscess by carbapenem-resistant Klebsiella pneumonia , 2019, British journal of neurosurgery.

[10]  G. Poulakou,et al.  The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How , 2019, Front. Public Health.

[11]  C. Colombo,et al.  Successful ceftazidime‐avibactam treatment of post‐surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[12]  H. Patel,et al.  Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime , 2018, Drug Research.

[13]  Marc Whitman,et al.  Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin. , 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[14]  J. Rodríguez-Baño,et al.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae , 2018, Clinical Microbiology Reviews.

[15]  M. Kollef,et al.  Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. , 2017, The Lancet. Infectious diseases.

[16]  J. Zunt,et al.  2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  B. Kreiswirth,et al.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Y. Carmeli,et al.  Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms , 2016, Antimicrobial Agents and Chemotherapy.

[19]  D. Paterson,et al.  Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. , 2016, The Journal of antimicrobial chemotherapy.

[20]  Paul Newell,et al.  Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Y. Carmeli,et al.  Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. , 2016, The Lancet. Infectious diseases.

[22]  O. Sipahi,et al.  Carbapenem-resistant Klebsiella pneumoniae meningitis: A case report , 2016, Journal of chemotherapy.

[23]  J. Mazuski,et al.  Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  A. Vakis,et al.  Infections in patients undergoing craniotomy: risk factors associated with post-craniotomy meningitis. , 2015, Journal of neurosurgery.

[25]  Bilgul Mete,et al.  Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[26]  J. Karlowsky,et al.  Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections , 2014, Core evidence.

[27]  E. García-Cabrera,et al.  Infecciones relacionadas con los sistemas de drenaje de líquido cefalorraquídeo , 2008 .

[28]  T. Walley,et al.  Outcomes , 1995, Too Many Lawyers?.

[29]  M. Paul,et al.  Risk factors for meningitis in neurosurgical patients with cerebrospinal fluid drains: prospective observational cohort study , 2019, Acta Neurochirurgica.

[30]  Telework Supports.  General information , 2018, 2018 IEEE International Conference on Consumer Electronics-Taiwan (ICCE-TW).

[31]  G. Britz,et al.  Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report , 2018, The Journal of antimicrobial chemotherapy.